



Published in final edited form as:

Pediatr Res. 2021 May ; 89(6): 1373–1379. doi:10.1038/s41390-020-01125-7.

It's All in the Milk: Chondroitin Sulfate as Potential Preventative Therapy for Necrotizing Enterocolitis

Thomas A. Knowles, Brian D Hosfield, Anthony R. Pecoraro, Hongge Li, W. Christopher Shelley, Troy A. Markel

Department of Surgery, Section of Pediatric Surgery, Riley Hospital for Children at Indiana University Health and The Indiana University School of Medicine, Indianapolis, IN

Abstract

Necrotizing enterocolitis (NEC) is a devastating condition affecting up to 5% of NICU admissions. Risk factors include preterm delivery, low birth weight, and antibiotic use. The pathogenesis is characterized by a combination of intestinal ischemia, necrosis of the bowel, reperfusion injury, and sepsis typically resulting in surgical resection of afflicted bowel. Targeted medical therapy remains elusive. Chondroitin sulfate (CS) holds the potential to prevent the onset of NEC through its anti-inflammatory properties and protective effect on the gut microbiome. The purpose of this review is to outline the many properties of CS to highlight its potential use in high risk infants and attenuate the severity of NEC. The purpose of this review is to 1) Discuss the interaction of CS with the infant microbiome, 2) Review the anti-inflammatory properties of CS, and 3) Postulate on the potential role of CS in preventing necrotizing enterocolitis.

INTRODUCTION

Necrotizing enterocolitis (NEC) is responsible for 2-5% of all NICU admissions worldwide. (1) The majority of cases involve preterm infants, with an incidence rate of 7-9% in the very low birth weight (VLBW) population. (2, 3) Targeted medical treatment for NEC is limited and many infants often require surgery. Due to the rapid progression of the disease, infants with NEC are often diagnosed when the disease is advanced and requires surgery, thereby increasing morbidity, mortality and cost burden. (4, 5) Despite extensive research there has been no significant advances in treating NEC over the past 30 years.

Preventative treatment for most diseases requires an adept understanding of its etiology and pathophysiology. Proposing an effective solution NEC is difficult as its pathophysiology remains poorly understood. There are several theories concerning the pathophysiology of NEC. One theory is that unfavorable intestinal bacterial colonization, called dysbiosis, disrupts the mucosal lining triggering an acute inflammatory response allowing bacteria to

Correspondence: Troy A. Markel, MD, Associate Professor of Surgery, Indiana University School of Medicine, Riley Hospital for Children at IU Health, 705 Riley Hospital Dr., RI 2500, Indianapolis, IN 46202, Ph: 317-437-2506, Fax; 317-274-4491, tmarkel@iupui.edu.

Author contributions: TAK drafted the manuscript, made critical revisions, and approved the final submission. BDH, ARP, HL, WCS, and TAM all made critical revisions to the manuscript and approved its final submission.

Consent: This was not a clinical trial and human research wasn't conducted. Consent was not required

Disclosures: No Disclosures or conflicts of interest

translocate from the gut to the bloodstream. This process is associated with dysfunction of intestinal microcirculation, hypoxia, and eventual necrosis and perforation of the bowel.

Preterm infants are especially susceptible to NEC for variety of reasons. The preterm immune system is immature and more likely to mount an excessive inflammatory response towards invasive gut flora. (6) Compounding this, preterm infants have higher intestinal permeability and are at increased risk of the translocation of bacteria. (7) Newborns also have decreased mucosal defenses against pathogens, including a deficiency of IgA and lactoferrin, making them more susceptible to inflammatory disease.(8)

Fortunately, there is one well-established method to reduce the chance of newborns developing NEC: breast milk. It has been well studied that the administration of human breast milk (HM) provides a dose-dependent protective effect against NEC, reducing incidence by as much as 4%. (9, 10) HM also decreases rates of mortality and other conditions such as retinopathy, sepsis, and bronchopulmonary dysplasia. (11, 12) Preterm babies fed exclusively formula have a 6-10 times higher rate of NEC occurrence compared to the HM fed group. (13) The mechanism behind such protection is multivariate. HM has been shown to alter the composition of the gut microbiome as well as alter gene expression in enterocytes. (14, 15) Many compounds derived from HM have shown immune modulating activity (Table 1)(16).

While HM, particularly maternal derived HM, is very effective at reducing risk for NEC, there are several disparities in its availability to infants in NICU's across the United States. Only 72% of infants in the NICU actually receive HM, leaving a significant number relying on formula feeds. (5, 17) These disparities are further associated with race, ethnicity, socioeconomic status, language, and sexual orientation of the parents. (18).

Choosing the most efficacious compounds in HM to fortify formula has great potential for reducing the incidence of NEC (Figure 1). HM contains many protective factors including secretory IgA, lactoferrin, and various oligosaccharides, that are not in formulas. [3] One such oligosaccharide that is gaining interest is the glycosaminoglycan chondroitin sulfate (CS). Traditionally used to slow the progression of osteoarthritis, isolated CS is a growing candidate to reduce intestinal inflammation and combat dysbiosis in preterm infants or those with inflammatory disease. (19–21) The purpose of this review is to 1) Discuss the interaction of CS with the infant microbiome, 2) Review the anti-inflammatory properties of CS, and 3) Postulate on the potential role of CS in preventing necrotizing enterocolitis as a supplement in formula feeds.

INFANT GUT MICROBIOME

To better understand the relationship between CS and the intestinal microbiome, it is best to discern the gut flora of healthy, full-term infants first. Each person has a uniquely structured composition of organisms that play a personalized role in digestion, immune activity, and neurologic signaling. (22) This system coalesces from the beginning of development, but only forms a true ecosystem after birth. The gut microbiome of a healthy infant undergoes three distinct stages of evolution starting at three months of age. According to data from

over 900 children, large amounts of *Bifidobacterium* are a hallmark of the first year of life and are heavily influenced by HM feeding. This is supported by other studies showing the colonization of anaerobes like *Bifidobacterium* and *Bacteroides* as important in the first weeks of life. (23) The first days to weeks of life are of particular interest, as NEC most often occurs during these times. (24) Fortunately some data that suggests controlled environments such as the NICU foster predictable patterns of infant gut colonization, allowing for insight on factors at play during this time.(25) These factors include antibiotic use, mode of childbirth, and feeding patterns. (26)

Despite the complexity, two major themes persist. The first is diversity. Many studies have demonstrated a strong correlation between the range of microbial species and disease. Alpha diversity, characterized by the number of taxonomic groups and distribution of the abundances of the groups, summarizes the structure and richness of a microbial community. (27) Loss of alpha diversity in adult gut flora has been seen in inflammatory bowel disease, obesity, and colitis as well as neurological disorders like Alzheimer disease. (28–30) NEC and Celiac disease are also associated with lower alpha diversity. (31–33) Contrary to these results, some studies have found no significant difference in species diversity in the stool of NEC and control patients. (34, 35) This can be explained by the fact that not all NEC patients harbor a dysbiotic gut. A preterm infant with microbial profile of that a “healthy” infant may still develop NEC if insult to the bowel comes in the form of ischemia or inflammation. Loss of alpha diversity may only increase the risk of NEC, not cause it. However, a plethora of data support diversity as a protective factor. (1, 31, 36, 37) Whether too much diversity is detrimental is also not understood. Until more data emerges, it is likely best to consider loss of alpha diversity as a risk factor for dysbiosis and NEC pathogenesis.

The second theme in the microbiome is balance. In most cases, a higher ratio of commensal bacteria protects the bowel by preventing pathogenic organisms from attaching to intestinal endothelium and causing inflammation. (38, 39) If a large amount of non-commensal species overtakes the gut, the balance may tip in favor of NEC pathogenesis. For example, infants born vaginally are predominantly colonized by *Firmicutes* such as *Lactobacillus spp.*, characteristic of the mother’s vaginal canal and stool. Once born, babies fed with HM commonly host large amounts of *Lactobacillus* and *Bifidobacteria* that play multiple roles in preventing dysbiosis. (40) Formula fed infants demonstrate increased levels of *E. coli*, *C. difficile*, and *B. fragilis*. If this effect profound enough, it may disrupt balance in the infant microflora. Such a scenario may explain the higher incidence of NEC in formula fed infants. (41) Paradoxically, studies show that formula infants have a more diverse microbiome, which is unexpected as formula feeding is associated with worse health outcomes. (42, 43) Perhaps excessive diversity can negatively impact the balance of commensal to pathogenic flora in the gut. However, these findings are controversial. (44) The detrimental effects of formula feeding may be better explained by the hyperosmolarity of formula regimens that damage the endothelial lining and microcirculation of the gut, likely offsetting any beneficial effect of increased diversity. (45)

DYSBIOSIS AND PRETERM INFANTS

There is no single pathogen that can cause dysbiosis, as the microflora is a complex ecosystem. Even though the triggers are multi-factorial and the pathogenesis can be variable, dysbiosis frequently involves loss of diversity or balance in the microflora. (1, 31, 46, 47) It typically displays a disproportionate colonization of invasive LPS containing gram-negative species that trigger inflammatory cascades and can prevent the growth of important obligate anaerobes like *Bifidobacterium* or protective species like *Bacteroides*. (48) In particular, dysbiosis is strongly linked with large increases in the number of gram-negative bacteria as infants age. For example, the most commonly seen species in stools of NEC infants are *Escherichia coli*, *Salmonella enteritica*, and various members of the Enterobacteriaceae and Pseudomonades families. (49–51) This is further supported by a case study finding that the relative amounts of gram-negative *Proteobacteria* such as *Klebsiella* was larger compared to the amounts of *Firmicutes* such as *Lactobacillus* (52). Until our understanding of the role of the microbiome in the infant gut increases, attenuating dysbiosis in NEC infants may best be approached from a broad view of the entire gut profile rather than focusing on targeting specific microbes.

Because undergoing preterm delivery is a such a strong risk factor for NEC, the microbiome profile of such infants is of great interest as it fits many patterns key to dysbiosis. The flora of preterm infants typically harbors a larger ratio of *Proteobacteria* compared to term infants. (23) An overabundance of *Staphylococci* bacteria has been documented in VLBW preterm infant stool as well. (53–55) Furthermore, one study found a reduced percentage of *Bacteroidaceae* and increased percentage of *Lactobacillaceae* in preterm infant stool compared to that of term infants.(56) These findings may be explained by extensive antibiotic use in preterm infants. Commonly used antibiotics for neonates are Ampicillin and Gentamicin. Despite their usefulness in fighting infection, prolonged use of such drugs has been correlated with a two-fold increase in NEC incidence. (57) Evidence shows that antibiotic use in preterm infants lowers the bacterial diversity necessary to keep *Proteobacteria* or invasive gram negative populations in check. (48, 58) Excessive administration of these drugs may tip the balance the microflora ecosystem to an unfavorable state conducive to NEC. Perhaps a simultaneous look into reducing antibiotic use and CS therapy will prove fruitful.

CHONDROITIN SULFATE AS PREVENTATIVE THERAPY

CS has many intriguing properties, particularly in the extracellular matrix. As a derivative of the glycosaminoglycan family of connective tissue structures, it is found naturally in humans in HM, cartilage, nervous structures, and various organs playing both structural and physiologic roles. (59) CS is a polymer of alternating and repeating sequences of glucuronic acid and galactosamine typically sulfated at the C4 and C6 position. Like other glycosaminoglycans, this structure enables endogenous CS to bind various core proteins forming proteoglycans. This formation is not simply structural, as CS derived proteoglycans appear to regulate cell signaling in different pathways and locations throughout the body. (60–62)

CS separates itself from other glycosaminoglycans and oligosaccharides as a candidate for formula supplementation in a few ways. One way is in the diversity of its biologic activity. In addition to sharing probiotic and anti-inflammatory properties with other compounds in HM, CS appears unique its propensity to increase sulfate reducing bacteria populations. (21, 63) CS also holds various antioxidant and antithrombotic properties.(64–67) This is important, as the concentration of CS in HM appears to change over time. Preterm mothers harbor more CS in their milk than term mothers.(68, 69) Perhaps there is an evolutionary advantage to having more CS available in HM for mothers caring for preterm infants.

Another way CS differentiates itself is its extensive clinic use as an anti-inflammatory agent in osteoarthritis (OA). CS has been shown to upregulate hyaluronic acid and type 2 collagen synthesis in human chondrocytes, prevent apoptosis of chondrocytes in animal models, and regulate chondrocyte signaling. (70) However, its anti-inflammatory properties are of most interest for CS's potential use for NEC patients. Several OA related animal studies have shown its propensity to limit synthesis of pro-inflammatory mediators like nitric oxide, prostaglandin E₂, and NF- κ B mediated products (70) Similarly, serum levels of cytokines IL-1, TNF α , and IL-6 were reduced in rats given varying doses of oral CS. (71) Immune dysregulation and intestinal inflammation is part of the pathophysiology of NEC, and these anti-inflammatory properties of CS may provide benefits in a NEC animal model.

Traditionally, oral CS is used for OA patients. Its pharmacokinetic properties and bioavailability have been studied extensively in the OA model. It is administered orally at doses from 800 to 1200 mg/day and is primarily absorbed by the distal GI tract in the paracellular pathway. (70, 72) It is absorbed in relatively small amounts in the small intestine likely through endocytosis. CS is not significantly metabolized in the stomach or small intestine, but is mostly metabolized distal to the ileum. (72) Estimates on the exact bioavailability of oral CS range from 10% to 20%, with the majority of the absorbed CS being the form of depolymerized derivatives (70, 73) While there is some debate on the exact bioavailability, it is known that peak concentrations occur at 2 to 6 hours after dosage. CS is not metabolized by the cytochrome P450 system, it follows first order kinetics, and is a long acting drug, with a slow onset of action and biologic effect that can accumulate over the course of months. (70, 73) The half-life of CS in humans is 15 hours and steady state concentrations have been achieved after 4 days of oral therapy. It is important to note that clinical trials of CS in OA patients have reported no major side effects nor elevations of serum enzymes. (59) The FDA rates CS as "Generally Recognized as Safe". A few separated case reports have linked liver toxicity to glucosamine and CS therapy, but it remains unclear whether CS was a causal agent. CS is well tolerated, with few reported cases of an immune-allergic response. (59)

Since NEC primarily affects the small intestine a question remains regarding CS's therapeutic potency if it is not absorbed and metabolized significantly until the distal GI tract. One possible explanation is that CS may function through bacterial pathways as intestinal flora metabolize CS throughout the GI tract.(21) A second theory is CS needs to be absorbed systemically before it can act to reduce inflammation in the small intestine. Another major concern for CS supplementation is the effect of the pasteurization process on the biologic components of donor and formula feeds. Some data suggests that pasteurization

reduces levels of key components of HM such as IgA, growth factors, and other enzymes. (74) Fortunately, the times and temperatures involved appear unable to degrade CS or reduce concentrations of glycosaminoglycans.(75) CS supplemented feeds can theoretically still be pasteurized.

CHONDROITIN SULFATE AND THE MICROBIOME

Given that the pathophysiology of NEC involves intestinal dysbiosis and decrease alpha diversity, medications that promote a diverse and balanced microbiome have preventative potential. For CS to work it must be absorbed by resident microflora as well as enterocytes. Studies on antibiotic use demonstrate varying levels of CS fractional absorption, thus there must be some interplay between CS, the microflora, and the body. (21) The exact details of how CS influences the microbiome are not yet known. However, CS appears to work through three mechanisms: 1) Promoting growth of commensal genera in the microflora to maintain diversity and balance, 2) decreasing the invasion of pathogenic bacteria across the gut wall, and 3) increasing relative abundance of sulfate reducing bacteria.

CHONDROITIN SULFATE INDUCES GROWTH OF COMMENSAL MICROFLORA

Evidence suggests that CS exposure promotes growth of certain species of gut-protective bacteria. This effect can be seen with both isolated CS as well as HM, which contains CS. A review by Shmagel et al. analyzed eight studies performed on the effects of CS and glucosamine administration on the microbiome in both mouse and human models. They found “moderate-quality” evidence that CS exposure increased the relative abundance of genus *Bacteroides*, an important player in the early colonization of the infant gut. (21) Two of the analyzed studies using the mouse model noted an increase in the *Desulfovibrio piger* population, a sulfate reducing bacteria. In terms of overall gut diversity, they found mixed results.(21) Similar conclusions were found in study by Liu et al. They found that long term CS administration decreased blood LPS levels, reduced prevalence of *Proteobacteria* in stool, and increased intestinal *Bacteroides* populations. (76) These findings were supported by another study done by Ford et al. Rather than isolated CS, Ford and colleagues investigated the effects of HM on the microbiome of VLBW infants. Perhaps the most interesting aspect of their work was their separation of maternal HM and donor HM. The stool samples from infants receiving majority maternal HM had increased gut diversity, *Bacteroides*, and *Bifidobacterium* populations compared to the donor HM group. (36) If such is the case, then increasing the supply of readily available maternal HM for VLBW infants may improve patient outcomes and reduce cost of care. By extension, if the effect of HM depends on its source (maternal or donor), then structural or physiological properties of CS between sources may slightly differ as well. This has not been studied, but is supported by the fact that CS from different species, like shark or bovine, are absorbed at different rates in humans. (59) Further inquiry may unveil interesting conclusions. Taking these findings into account, increasing the abundance of genera such as *Bacteroides* may appear counterintuitive to an effort of promoting diversity. However, such genera are typically less populous in NEC infants (34, 77) CS exposure may restore a healthy balance in microflora lacking *Bacteroides* or *Bifidobacterium*. Such a restoration may lower the relative abundance of invasive gram negative bacteria, potentially reducing the risk of NEC development.

CHONDROITIN SULFATE LIMITS TRANSLOCATION OF GUT BACTERIA

Another potential beneficial property of CS is its ability to limit translocation and invasion of bacteria into the bloodstream. Burge et al. used an in vitro model with T84 cells formed in a monolayer and treated with CS. The cells were then exposed to *E. coli* and evaluated for inflammatory markers, cell viability, and transposition of the bacteria across the monolayer. Bacterial translocation was measured using trans-epithelial electrical resistance to gauge tight junction integrity. They described a concentration dependent effect, with no loss of cell function at CS concentrations up to 750 ug/ml. At the same amount, there was a 75% decrease in bacterial translocation and invasion across the cell monolayer. (78) Translating the value 750ug/ml to clinical terms is difficult, as ingesting a prescribed dosage of CS will not necessarily lead to similar intestinal concentrations. The gut is not a simple monolayer of cells. For context, peak serum concentrations of oral CS typically fall within the range of 2-12 ug/ml for OA patients. (70, 73) The side effect profile of CS minimizes any adverse outcomes or potential cellular damage if intestinal concentrations do exceed the 750ug/ml threshold. Most importantly, these findings by Burge and colleagues were consistent with the anti-inflammatory properties of CS.

Increasing the thickness or number of barriers will also prevent translocation of pathogenic species. This can be best understood by considering that chondroitin is a component of mucin. Mucin acts as a natural physical barrier to luminal bacteria and is secreted by goblet cells in the intestinal tract. Increasing the supply of CS in the environment will theoretically allow for increased production of mucin. (21) Many members of the genus *Bacteroides* are known to metabolize dietary glycans like CS in the gut. (79) If starved, these bacteria will break down mucin and induce inflammation and eventually translocation of bacteria. (80)

ANTI-INFLAMMATORY PROPERTIES OF CHONDROITIN SULFATE

The pathophysiology of NEC is extremely complex and involves more than the microbiome. Inflammation plays a central role. While the etiology behind the inflammation is still unclear, how the immature innate immune system increases susceptibility to NEC has been studied. It has been reported that immature intestine has underdeveloped expression of I κ B, a mediator that normally limits NF- κ B.(6) In theory this would lead to exaggerated NF- κ B related cascades and higher levels of pro-inflammatory markers such as IL-1, IL-6, IL-8, and TNF α . This is supported by a study analyzing human enterocytes. It found that immature cells secreted a larger amount of IL-8 in response to stimulation compared to mature cells. (81) These findings make sense in the context of Toll-Like receptor (TLRs) expression, specifically TLR4. LPS from pathogenic bacteria activate TLR4, which in turn induces activity of NF- κ B. A study by Zhou et al. concluded that TLR4 deficient mice experienced decreased amounts of enterocyte apoptosis and TNF α levels in a NEC model compared to wild type counterparts. They also found NEC severity was also attenuated in TLR4 deficient mice.(82) Thus, reducing pro-inflammatory markers in preterm infants may be useful in preventing NEC pathogenesis. While research into this approach limited, there are some studies investigating reducing the aberrant inflammatory response in NEC. [11, 82] Compounds like glucocorticoids and anti-cytokines have been used for prevention of NEC but hold concerning side effect profiles. (8) CS presents as a safe alternative for its

use for NEC. Exact profiling of the anti-inflammatory properties of CS remains elusive, but mounting evidence unveils many mechanisms behind them. These mechanisms include its inhibition of NF- κ B activity and its regulation of immune mediator cells like macrophages and mast cells. (Figure 2)

CHONDROITIN SULFATE LIMITS NF- κ B ACTIVITY

NF- κ B plays a central role in the inflammatory pathway of the immune system by mediating the secretion of acute phase reactants like IL-1, IL-6, and TNF α . (83) The therapeutic potential of CS therefore hinges on its ability to limit NF- κ B to reduce the severity of NEC. Research into this primarily involves the use of chondroitin sulfate for OA. Stabler et. al investigated the capacity for CS to limit NF- κ B expression in THP-1 macrophages. They cultured macrophages and treated them with the NF- κ B activators LPS and hyaluronic acid to induce an inflammatory response. They concurrently exposed the macrophages to varying levels of CS. Results showed that CS reduced release of IL-1 and blocked NF- κ B expression from activated macrophages compared to controls. (84) Another study investigated the capacity for CS to limit inflammatory markers in healthy patients. Navarro et al. conducted a randomized, double blind control trial with a patient cohort screened for medical concerns. Experimental groups received oral capsules of combined CS and glucosamine. The results revealed a significant drop in serum C-reactive protein in the experimental group compared to placebo. (85) Using KEGG and Gene Ontology databases, Navarro and colleagues also conducted gene-set enrichment pathway analysis and found significant reduction in cytokine-cytokine receptor interaction, JAK/STAT signaling, and intestinal IgA production. (85) A study by Campo et al. supported these findings. Using mouse articular chondrocytes stimulated by LPS to induce an inflammatory state, they found that CS blunted the response by reducing TNF α , IL-1, IL-6, and IFN γ levels. (86) Data from Chan et al. concluded that CS supplementation, in combination with glucosamine, also reduced IL-1 induced gene expression of NF- κ B, prostaglandin E, iNOS, and COX-2 in a bovine cartilage model. (87)

A potential drawback for CS to antagonize NF- κ B activity is its potential to sequester TGF- β 2 in the gut lumen. TGF- β 2 is an immune modulator that limits macrophage expression of cytokines through the NF- κ B pathway. A study by Namachivayam et al. used various techniques to measure TGF- β 2 bioactivity in the presence of different compounds derived from HM. They found that CS could bind milk-borne TGF- β 2 and limit its ability as an anti-inflammatory molecule. When the HM was treated with Chondroitinase, the bioactivity of TGF- β 2 increased.(88) Also, evidence suggests that isolated CS cannot directly trigger or interact with TLRs.(89) These revelations appear concerning for the potential of CS to limit NF- κ B activity. However, the study by Namachivayam et al. had a small sample size and only focused on aqueous factors of HM, not the fat compartment which contains significant amounts of TGF-B2.(88) Since CS is mainly degraded in the large intestine, trapped TGF- β 2 can still act distally.(70) CS potentially limits NF- κ B from a multi-faceted approach as discussed earlier. It is likely that any pro-inflammatory aspects of CS are outweighed by the many anti-inflammatory ones. Further inquiry may dissolve any ambiguity.

CHONDROITIN SULFATE AND IMMUNE CELLS

The capacity for CS to regulate the activity of various immune cells holds much interest. Tan et al. measured the effect of CS on expression of inflammatory mediators in macrophages derived from mouse bone marrow. Results concluded that CS reduced expression of IL-6 and TNF α by macrophages activated by LPS and INF γ . Expression of IL-10 increased. (90) This suggests that CS alters the phenotype of macrophages away from an inflammatory role towards an anti-inflammatory state conducive to wound healing. The macrophages pretreated with CS prior to exposure of LPS or INF γ had the strongest decrease in inflammatory gene expression. (90) If these findings are replicated in the gut, then treating preterm or VLBW infants prophylactically with CS may reduce the risk of developing NEC. Tan and colleagues concluded that these effects were in part due to suppression of NF- κ B activity in macrophages.

CS also appeared to modulate the activity of mast cells. Gross et al. investigated the effect of CS on human mast cell secretion of TNF and CXCL8. They concluded that mast cells pretreated with CS and then activated with IL-33 exhibited a significant reduction of TNF and CXCL8 secretion. (91) Further inquiry revealed that CS did not alter gene expression of TNF and CXCL8, decrease IL-33 surface receptor localization, nor block mast cell degranulation. They did find that CS was endocytosed by mast cells in a calcium independent manner. (91) Gross and colleagues concluded that CS must act through an unknown intracellular mechanism to limit secretion of TNF and CXCL8. Whether the pathway involved NF- κ B or something else was unknown. Current understanding for the pathogenesis of NEC does not involve mast cells. However, their role in other intestinal disorders like inflammatory bowel disease opens the possibility of an undiscovered function in NEC patients. (92).

CONCLUSION

While our knowledge on pathogenesis of NEC is incomplete, reducing inflammation and preventing dysbiosis may reduce the severity of NEC and could reduce mortality in preterm and low birth weight infants. CS is an intriguing candidate for NEC therapy due to its safe side effect profile, its anti-inflammatory properties, and its favorable influence on the microbiome.

Funding:

This work was supported by K08DK113226 from the National Institutes of Health, the Koret Foundation, The George H. Clowe's Memorial Research Career Development Award, and the Department of Surgery at the Indiana University School of Medicine

REFERENCES

1. Gupta A, Paria A. Etiology and medical management of NEC. *Early Hum Dev.* 2016;97:17–23. [PubMed: 27080373]
2. Hull MA, Fisher JG, Gutierrez IM, Jones BA, Kang KH, Kenny M, et al. Mortality and management of surgical necrotizing enterocolitis in very low birth weight neonates: a prospective cohort study. *J Am Coll Surg.* 2014;218(6):1148–55. [PubMed: 24468227]

3. Knell J, Han SM, Jaksic T, Modi BP. Current Status of Necrotizing Enterocolitis. *Curr Probl Surg.* 2019;56(1):11–38. [PubMed: 30691547]
4. Li QY, An Y, Liu L, Wang XQ, Chen S, Wang ZL, et al. Differences in the Clinical Characteristics of Early- and Late-Onset Necrotizing Enterocolitis in Full-Term Infants: A Retrospective Case-Control Study. *Sci Rep.* 2017;7:43042. [PubMed: 28211488]
5. Boundy EO, Perrine CG, Nelson JM, Hamner HC. Disparities in Hospital-Reported Breast Milk Use in Neonatal Intensive Care Units - United States, 2015. *MMWR Morb Mortal Wkly Rep.* 2017;66(48):1313–7. [PubMed: 29216029]
6. Nanthakumar N, Meng D, Goldstein AM, Zhu W, Lu L, Uauy R, et al. The mechanism of excessive intestinal inflammation in necrotizing enterocolitis: an immature innate immune response. *PLoS One.* 2011;6(3):e17776. [PubMed: 21445298]
7. Ma B, McComb E, Gajer P, Yang H, Humphrys M, Okogbule-Wonodi AC, et al. Microbial Biomarkers of Intestinal Barrier Maturation in Preterm Infants. *Front Microbiol.* 2018;9:2755. [PubMed: 30487786]
8. Choi YY. Necrotizing enterocolitis in newborns: update in pathophysiology and newly emerging therapeutic strategies. *Korean J Pediatr.* 2014;57(12):505–13. [PubMed: 25653683]
9. Miller J, Tonkin E, Damarell RA, McPhee AJ, Sukanuma M, Sukanuma H, et al. A Systematic Review and Meta-Analysis of Human Milk Feeding and Morbidity in Very Low Birth Weight Infants. *Nutrients.* 2018;10(6).
10. Meinen-Derr J, Poindexter B, Wrage L, Morrow AL, Stoll B, Donovan EF. Role of human milk in extremely low birth weight infants' risk of necrotizing enterocolitis or death. *J Perinatol.* 2009;29(1):57–62. [PubMed: 18716628]
11. Herrmann K, Carroll K. An exclusively human milk diet reduces necrotizing enterocolitis. *Breastfeed Med.* 2014;9(4):184–90. [PubMed: 24588561]
12. Hair AB, Peluso AM, Hawthorne KM, Perez J, Smith DP, Khan JY, et al. Beyond Necrotizing Enterocolitis Prevention: Improving Outcomes with an Exclusive Human Milk-Based Diet. *Breastfeed Med.* 2016;11(2):70–4. [PubMed: 26789484]
13. Lucas A, Cole TJ. Breast milk and neonatal necrotising enterocolitis. *Lancet.* 1990;336(8730):1519–23. [PubMed: 1979363]
14. Sitarik AR, Bobbitt KR, Havstad SL, Fujimura KE, Levin AM, Zoratti EM, et al. Breast Milk Transforming Growth Factor beta Is Associated With Neonatal Gut Microbial Composition. *J Pediatr Gastroenterol Nutr.* 2017;65(3):e60–e7. [PubMed: 28827481]
15. Guner YS, Franklin AL, Chokshi NK, Castle SL, Pontarelli E, Wang J, et al. P-glycoprotein induction by breast milk attenuates intestinal inflammation in experimental necrotizing enterocolitis. *Lab Invest.* 2011;91(11):1668–79. [PubMed: 21788941]
16. Infant Formula: Evaluating the Safety of New Ingredients. Washington (DC)2004.
17. Profit J, Gould JB, Bennett M, Goldstein BA, Draper D, Phibbs CS, et al. Racial/Ethnic Disparity in NICU Quality of Care Delivery. *Pediatrics.* 2017;140(3).
18. Sigurdson K, Morton C, Mitchell B, Profit J. Correction: Disparities in NICU quality of care: a qualitative study of family and clinician accounts. *J Perinatol.* 2018;38(8):1123. [PubMed: 30042468]
19. Simental-Mendia M, Sanchez-Garcia A, Vilchez-Cavazos F, Acosta-Olivo CA, Pena-Martinez VM, Simental-Mendia LE. Effect of glucosamine and chondroitin sulfate in symptomatic knee osteoarthritis: a systematic review and meta-analysis of randomized placebo-controlled trials. *Rheumatol Int.* 2018;38(8):1413–28. [PubMed: 29947998]
20. Hori Y, Hoshino J, Yamazaki C, Sekiguchi T, Miyauchi S, Horie K. Effects of chondroitin sulfate on colitis induced by dextran sulfate sodium in rats. *Jpn J Pharmacol.* 2001;85(2):155–60. [PubMed: 11286397]
21. Shmagel A, Demmer R, Knights D, Butler M, Langsetmo L, Lane NE, et al. The Effects of Glucosamine and Chondroitin Sulfate on Gut Microbial Composition: A Systematic Review of Evidence from Animal and Human Studies. *Nutrients.* 2019;11(2).
22. Franzosa EA, Huang K, Meadow JF, Gevers D, Lemon KP, Bohannon BJ, et al. Identifying personal microbiomes using metagenomic codes. *Proc Natl Acad Sci U S A.* 2015;112(22):E2930–8. [PubMed: 25964341]

23. Staude B, Oehmke F, Lauer T, Behnke J, Gopel W, Schloter M, et al. The Microbiome and Preterm Birth: A Change in Paradigm with Profound Implications for Pathophysiologic Concepts and Novel Therapeutic Strategies. *Biomed Res Int.* 2018;2018:7218187. [PubMed: 30370305]
24. Gonzalez-Rivera R, Culverhouse RC, Hamvas A, Tarr PI, Warner BB. The age of necrotizing enterocolitis onset: an application of Sartwell's incubation period model. *J Perinatol.* 2011;31(8):519–23. [PubMed: 21273988]
25. La Rosa PS, Warner BB, Zhou Y, Weinstock GM, Sodergren E, Hall-Moore CM, et al. Patterned progression of bacterial populations in the premature infant gut. *Proc Natl Acad Sci U S A.* 2014;111(34):12522–7. [PubMed: 25114261]
26. Yang I, Corwin EJ, Brennan PA, Jordan S, Murphy JR, Dunlop A. The Infant Microbiome: Implications for Infant Health and Neurocognitive Development. *Nurs Res.* 2016;65(1):76–88. [PubMed: 26657483]
27. Willis AD. Rarefaction, Alpha Diversity, and Statistics. *Front Microbiol.* 2019;10:2407. [PubMed: 31708888]
28. Mosca A, Leclerc M, Hugot JP. Gut Microbiota Diversity and Human Diseases: Should We Reintroduce Key Predators in Our Ecosystem? *Front Microbiol.* 2016;7:455. [PubMed: 27065999]
29. Minter MR, Zhang C, Leone V, Ringus DL, Zhang X, Oyler-Castrillo P, et al. Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer's disease. *Sci Rep.* 2016;6:30028. [PubMed: 27443609]
30. Human Microbiome Project C Structure, function and diversity of the healthy human microbiome. *Nature.* 2012;486(7402):207–14. [PubMed: 22699609]
31. McMurtry VE, Gupta RW, Tran L, Blanchard EE, Penn D, Taylor CM, et al. Bacterial diversity and Clostridia abundance decrease with increasing severity of necrotizing enterocolitis. *Microbiome.* 2015;3:11. [PubMed: 25810906]
32. Stewart CJ, Marrs EC, Magorrian S, Nelson A, Lanyon C, Perry JD, et al. The preterm gut microbiota: changes associated with necrotizing enterocolitis and infection. *Acta Paediatr.* 2012;101(11):1121–7. [PubMed: 22845166]
33. Sanchez E, Nadal I, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y. Reduced diversity and increased virulence-gene carriage in intestinal enterobacteria of coeliac children. *BMC Gastroenterol.* 2008;8:50. [PubMed: 18983674]
34. Neu J, Pammi M. Pathogenesis of NEC: Impact of an altered intestinal microbiome. *Semin Perinatol.* 2017;41(1):29–35. [PubMed: 27986328]
35. Brower-Sinning R, Zhong D, Good M, Firek B, Baker R, Sodhi CP, et al. Mucosa-associated bacterial diversity in necrotizing enterocolitis. *PLoS One.* 2014;9(9):e105046. [PubMed: 25203729]
36. Ford SL, Lohmann P, Preidis GA, Gordon PS, O'Donnell A, Hagan J, et al. Improved feeding tolerance and growth are linked to increased gut microbial community diversity in very-low-birth-weight infants fed mother's own milk compared with donor breast milk. *Am J Clin Nutr.* 2019;109(4):1088–97. [PubMed: 30982856]
37. Dobbler PT, Procianoy RS, Mai V, Silveira RC, Corso AL, Rojas BS, et al. Low Microbial Diversity and Abnormal Microbial Succession Is Associated with Necrotizing Enterocolitis in Preterm Infants. *Front Microbiol.* 2017;8:2243. [PubMed: 29187842]
38. Houghteling PD, Walker WA. Why is initial bacterial colonization of the intestine important to infants' and children's health? *J Pediatr Gastroenterol Nutr.* 2015;60(3):294–307. [PubMed: 25313849]
39. Gareau MG, Sherman PM, Walker WA. Probiotics and the gut microbiota in intestinal health and disease. *Nat Rev Gastroenterol Hepatol.* 2010;7(9):503–14. [PubMed: 20664519]
40. Lin HC, Hsu CH, Chen HL, Chung MY, Hsu JF, Lien RI, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: a multicenter, randomized, controlled trial. *Pediatrics.* 2008;122(4):693–700. [PubMed: 18829790]
41. Hoyos AB. Reduced incidence of necrotizing enterocolitis associated with enteral administration of *Lactobacillus acidophilus* and *Bifidobacterium infantis* to neonates in an intensive care unit. *Int J Infect Dis.* 1999;3(4):197–202. [PubMed: 10575148]

42. Dieterich CM, Felice JP, O'Sullivan E, Rasmussen KM. Breastfeeding and health outcomes for the mother-infant dyad. *Pediatr Clin North Am*. 2013;60(1):31–48. [PubMed: 23178059]
43. Thompson AL, Monteagudo-Mera A, Cadenas MB, Lampl ML, Azcarate-Peril MA. Milk- and solid-feeding practices and daycare attendance are associated with differences in bacterial diversity, predominant communities, and metabolic and immune function of the infant gut microbiome. *Front Cell Infect Microbiol*. 2015;5:3. [PubMed: 25705611]
44. Ho NT, Li F, Lee-Sarwar KA, Tun HM, Brown BP, Pannaraj PS, et al. Meta-analysis of effects of exclusive breastfeeding on infant gut microbiota across populations. *Nat Commun*. 2018;9(1):4169. [PubMed: 30301893]
45. Steele JR, Meskell RJ, Foy J, Garner AE. Determining the osmolality of over-concentrated and supplemented infant formulas. *J Hum Nutr Diet*. 2013;26(1):32–7. [PubMed: 23210913]
46. Kriss M, Hazleton KZ, Nusbacher NM, Martin CG, Lozupone CA. Low diversity gut microbiota dysbiosis: drivers, functional implications and recovery. *Curr Opin Microbiol*. 2018;44:34–40. [PubMed: 30036705]
47. Wang Z, Xu CM, Liu YX, Wang XQ, Zhang L, Li M, et al. Characteristic dysbiosis of gut microbiota of Chinese patients with diarrhea-predominant irritable bowel syndrome by an insight into the pan-microbiome. *Chin Med J (Engl)*. 2019;132(8):889–904. [PubMed: 30958430]
48. Tanaka S, Kobayashi T, Songjinda P, Tateyama A, Tsubouchi M, Kiyohara C, et al. Influence of antibiotic exposure in the early postnatal period on the development of intestinal microbiota. *FEMS Immunol Med Microbiol*. 2009;56(1):80–7. [PubMed: 19385995]
49. Mai V, Young CM, Ukhanova M, Wang X, Sun Y, Casella G, et al. Fecal microbiota in premature infants prior to necrotizing enterocolitis. *PLoS One*. 2011;6(6):e20647. [PubMed: 21674011]
50. Underwood MA, Sohn K. The Microbiota of the Extremely Preterm Infant. *Clin Perinatol*. 2017;44(2):407–27. [PubMed: 28477669]
51. Coggins SA, Wynn JL, Weitkamp JH. Infectious causes of necrotizing enterocolitis. *Clin Perinatol*. 2015;42(1):133–54, ix. [PubMed: 25678001]
52. Warner BB, Deych E, Zhou Y, Hall-Moore C, Weinstock GM, Sodergren E, et al. Gut bacteria dysbiosis and necrotizing enterocolitis in very low birthweight infants: a prospective case-control study. *Lancet*. 2016;387(10031):1928–36. [PubMed: 26969089]
53. de la Cochetiere MF, Piloquet H, des Robert C, Darmaun D, Galmiche JP, Roze JC. Early intestinal bacterial colonization and necrotizing enterocolitis in premature infants: the putative role of Clostridium. *Pediatr Res*. 2004;56(3):366–70. [PubMed: 15201403]
54. Aujoulat F, Roudiere L, Picaud JC, Jacquot A, Filleron A, Neveu D, et al. Temporal dynamics of the very premature infant gut dominant microbiota. *BMC Microbiol*. 2014;14:325. [PubMed: 25551282]
55. Romano-Keeler J, Shilts MH, Tovchigrechko A, Wang C, Brucker RM, Moore DJ, et al. Distinct mucosal microbial communities in infants with surgical necrotizing enterocolitis correlate with age and antibiotic exposure. *PLoS One*. 2018;13(10):e0206366. [PubMed: 30365522]
56. Arboleya S, Sanchez B, Milani C, Duranti S, Solis G, Fernandez N, et al. Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics. *J Pediatr*. 2015;166(3):538–44. [PubMed: 25444008]
57. Kuppala VS, Meinzen-Derr J, Morrow AL, Schibler KR. Prolonged initial empirical antibiotic treatment is associated with adverse outcomes in premature infants. *J Pediatr*. 2011;159(5):720–5. [PubMed: 21784435]
58. Greenwood C, Morrow AL, Lagomarcino AJ, Altaye M, Taft DH, Yu Z, et al. Early empiric antibiotic use in preterm infants is associated with lower bacterial diversity and higher relative abundance of Enterobacter. *J Pediatr*. 2014;165(1):23–9. [PubMed: 24529620]
59. Volpi N Chondroitin Sulfate Safety and Quality. *Molecules*. 2019;24(8).
60. Kastana P, Choleva E, Poimenidi E, Karamanos N, Sugahara K, Papadimitriou E. Insight into the role of chondroitin sulfate E in angiogenesis. *FEBS J*. 2019;286(15):2921–36. [PubMed: 30932321]
61. Dyck S, Kataria H, Alizadeh A, Santhosh KT, Lang B, Silver J, et al. Perturbing chondroitin sulfate proteoglycan signaling through LAR and PTPsigma receptors promotes a beneficial inflammatory response following spinal cord injury. *J Neuroinflammation*. 2018;15(1):90. [PubMed: 29558941]

62. Uhlin-Hansen L, Eskeland T, Kolset SO. Modulation of the expression of chondroitin sulfate proteoglycan in stimulated human monocytes. *J Biol Chem*. 1989;264(25):14916–22. [PubMed: 2768247]
63. Pichette J, Fynn-Sackey N, Gagnon J. Hydrogen Sulfide and Sulfate Prebiotic Stimulates the Secretion of GLP-1 and Improves Glycemia in Male Mice. *Endocrinology*. 2017;158(10):3416–25. [PubMed: 28977605]
64. Liu X, Hao J, Shan X, Zhang X, Zhao X, Li Q, et al. Antithrombotic activities of fucosylated chondroitin sulfates and their depolymerized fragments from two sea cucumbers. *Carbohydr Polym*. 2016;152:343–50. [PubMed: 27516281]
65. Egea J, Garcia AG, Verges J, Montell E, Lopez MG. Antioxidant, antiinflammatory and neuroprotective actions of chondroitin sulfate and proteoglycans. *Osteoarthritis Cartilage*. 2010;18 Suppl 1:S24–7.
66. Pai VC, Lo IC, Huang YW, Tsai IC, Cheng HP, Shi GY, et al. The chondroitin sulfate moiety mediates thrombomodulin-enhanced adhesion and migration of vascular smooth muscle cells. *J Biomed Sci*. 2018;25(1):14. [PubMed: 29439742]
67. Zancan P, Mourao PA. Venous and arterial thrombosis in rat models: dissociation of the antithrombotic effects of glycosaminoglycans. *Blood Coagul Fibrinolysis*. 2004;15(1):45–54. [PubMed: 15166943]
68. Coppa GV, Gabrielli O, Zampini L, Galeazzi T, Maccari F, Buzzega D, et al. Glycosaminoglycan content in term and preterm milk during the first month of lactation. *Neonatology*. 2012;101(1):74–6. [PubMed: 21934331]
69. Coppa GV, Gabrielli O, Buzzega D, Zampini L, Galeazzi T, Maccari F, et al. Composition and structure elucidation of human milk glycosaminoglycans. *Glycobiology*. 2011;21(3):295–303. [PubMed: 21030540]
70. Henrotin Y, Mathy M, Sanchez C, Lambert C. Chondroitin sulfate in the treatment of osteoarthritis: from in vitro studies to clinical recommendations. *Ther Adv Musculoskelet Dis*. 2010;2(6):335–48. [PubMed: 22870459]
71. Korotky O, Vovk A, Blokhina O, Dvorshchenko K, Falalyeyeva T, Abenavoli L, et al. Effect of Chondroitin Sulfate on Blood Serum Cytokine Profile during Carrageenan-induced Edema and Monoiodoacetate-induced Osteoarthritis in Rats. *Rev Recent Clin Trials*. 2019;14(1):50–5. [PubMed: 30387401]
72. Barthe L, Woodley J, Lavit M, Przybylski C, Philibert C, Houin G. In vitro intestinal degradation and absorption of chondroitin sulfate, a glycosaminoglycan drug. *Arzneimittelforschung*. 2004;54(5):286–92. [PubMed: 15212191]
73. du Souich P. Absorption, distribution and mechanism of action of SYSADOAS. *Pharmacol Ther*. 2014;142(3):362–74. [PubMed: 24457028]
74. Nutrition ECo, Arslanoglu S, Corpeleijn W, Moro G, Braegger C, Campoy C, et al. Donor human milk for preterm infants: current evidence and research directions. *J Pediatr Gastroenterol Nutr*. 2013;57(4):535–42. [PubMed: 24084373]
75. Burge K, Bergner E, Gunasekaran A, Eckert J, Chaaban H. The Role of Glycosaminoglycans in Protection from Neonatal Necrotizing Enterocolitis: A Narrative Review. *Nutrients*. 2020;12(2).
76. Liu F, Zhang N, Li Z, Wang X, Shi H, Xue C, et al. Chondroitin sulfate disaccharides modified the structure and function of the murine gut microbiome under healthy and stressed conditions. *Sci Rep*. 2017;7(1):6783. [PubMed: 28754911]
77. Rotimi VO, Duerden BI. The bacterial flora of neonates with congenital abnormalities of the gastro-intestinal tract. *J Hyg (Lond)*. 1982;88(1):69–81.
78. Burge KY, Hannah L, Eckert JV, Gunasekaran A, Chaaban H. The Protective Influence of Chondroitin Sulfate, a Component of Human Milk, on Intestinal Bacterial Invasion and Translocation. *J Hum Lact*. 2019;35(3):538–49. [PubMed: 31051086]
79. Tuncil YE, Xiao Y, Porter NT, Reuhs BL, Martens EC, Hamaker BR. Reciprocal Prioritization to Dietary Glycans by Gut Bacteria in a Competitive Environment Promotes Stable Coexistence. *mBio*. 2017;8(5).

80. Salyers AA, Vercellotti JR, West SE, Wilkins TD. Fermentation of mucin and plant polysaccharides by strains of *Bacteroides* from the human colon. *Appl Environ Microbiol*. 1977;33(2):319–22. [PubMed: 848954]
81. Claud EC, Lu L, Anton PM, Savidge T, Walker WA, Cherayil BJ. Developmentally regulated IkappaB expression in intestinal epithelium and susceptibility to flagellin-induced inflammation. *Proc Natl Acad Sci U S A*. 2004;101(19):7404–8. [PubMed: 15123821]
82. Nanthakumar NN, Fusunyan RD, Sanderson I, Walker WA. Inflammation in the developing human intestine: A possible pathophysiologic contribution to necrotizing enterocolitis. *Proc Natl Acad Sci U S A*. 2000;97(11):6043–8. [PubMed: 10823949]
83. Zhang Q, Lenardo MJ, Baltimore D. 30 Years of NF-kappaB: A Blossoming of Relevance to Human Pathobiology. *Cell*. 2017;168(1-2):37–57. [PubMed: 28086098]
84. Stabler TV, Huang Z, Montell E, Verges J, Kraus VB. Chondroitin sulphate inhibits NF-kappaB activity induced by interaction of pathogenic and damage associated molecules. *Osteoarthritis Cartilage*. 2017;25(1):166–74. [PubMed: 27614315]
85. Navarro SL, White E, Kantor ED, Zhang Y, Rho J, Song X, et al. Randomized trial of glucosamine and chondroitin supplementation on inflammation and oxidative stress biomarkers and plasma proteomics profiles in healthy humans. *PLoS One*. 2015;10(2):e0117534. [PubMed: 25719429]
86. Campo GM, Avenoso A, Campo S, D'Ascola A, Traina P, Sama D, et al. Glycosaminoglycans modulate inflammation and apoptosis in LPS-treated chondrocytes. *J Cell Biochem*. 2009;106(1):83–92. [PubMed: 19009563]
87. Chan PS, Caron JP, Orth MW. Short-term gene expression changes in cartilage explants stimulated with interleukin beta plus glucosamine and chondroitin sulfate. *J Rheumatol*. 2006;33(7):1329–40. [PubMed: 16821268]
88. Namachivayam K, Coffing HP, Sankaranarayanan NV, Jin Y, MohanKumar K, Frost BL, et al. Transforming growth factor-beta2 is sequestered in preterm human milk by chondroitin sulfate proteoglycans. *Am J Physiol Gastrointest Liver Physiol*. 2015;309(3):G171–80. [PubMed: 26045614]
89. Frey H, Schroeder N, Manon-Jensen T, Iozzo RV, Schaefer L. Biological interplay between proteoglycans and their innate immune receptors in inflammation. *FEBS J*. 2013;280(10):2165–79. [PubMed: 23350913]
90. Tan GK, Tabata Y. Chondroitin-6-sulfate attenuates inflammatory responses in murine macrophages via suppression of NF-kappaB nuclear translocation. *Acta Biomater*. 2014;10(6):2684–92. [PubMed: 24561712]
91. Gross AR, Theoharides TC. Chondroitin sulfate inhibits secretion of TNF and CXCL8 from human mast cells stimulated by IL-33. *Biofactors*. 2019;45(1):49–61. [PubMed: 30521103]
92. De Winter BY, van den Wijngaard RM, de Jonge WJ. Intestinal mast cells in gut inflammation and motility disturbances. *Biochim Biophys Acta*. 2012;1822(1):66–73. [PubMed: 21497195]
93. Green Corkins K, Shurley T. What's in the Bottle? A Review of Infant Formulas. *Nutr Clin Pract*. 2016;31(6):723–9. [PubMed: 27646861]
94. Vandenplas Y, Zakharova I, Dmitrieva Y. Oligosaccharides in infant formula: more evidence to validate the role of prebiotics. *Br J Nutr*. 2015;113(9):1339–44. [PubMed: 25989994]

Impact:

- NEC is a costly medical burden in the United States
- Breastmilk is the best preventative measure for NEC, but not all infants in the NICU have access to breastmilk
- Novel therapies and diagnostic tools are needed for NEC
- Chondroitin sulfate may be a potential therapy for NEC due to its potent anti-inflammatory properties
- Chondroitin sulfate could be added to formula in an attempt to mitigate breastmilk disparities



Ingredient	Present in Formula?
Lactoferrin	no
Proteins, nucleic acids, sugars	yes
Secretory IgA	no
Hemagglutinin inhibitor	no
Mucin	no
Oligosaccharides	yes
Uric Acid	no
Granulocyte-colony stimulating factor	no
Lysozymes	no
Cytokines	no
Glycosaminoglycans (CS)	no




Figure 1: Human breastmilk has many protective properties.
 Multiple protective compounds are found in breastmilk.(93, 94)

Anti-inflammatory and Protective Properties of CS




Figure 2: Potential Mechanisms of CS in the neonatal population

Chondroitin sulfate works to decrease proinflammatory mediators while working to modulate the intestinal microbiome.

Table 1:
List of studied immune-active compounds in human breast milk.

This table is adapted from a book prepared at the request of the Food and Drug Administration about regulatory and research issues surrounding human breast milk infant formula. Many compounds listed are not in infant formula (16)

Ingredient	Function
Catalase	Breaks down hydrogen peroxide and limits bacterial translocation of intestinal barrier
Granulocyte-colony stimulating factor	Induces migration and proliferation of endothelial cells
Hemagglutinin inhibitor	Prevents bacterial adherence to intestinal lining by blocking hemagglutinin activity
Immunoglobulin G	Binds to and immobilizes microbes and modulates immune responses
Interleukin-8	Chemotaxis factor for neutrophil response towards invasive bacteria
Interleukin-10	Down regulates inflammatory cytokine synthesis
Lactoferrin	Sequesters iron supply away from pathogenic bacteria
Lysozyme	Limits inflammation and holds bactericidal activity
Mucin	Inhibits bacteria and other microbes from attaching to intestinal lining
Oligosaccharides & polysaccharides	Various anti-inflammatory properties and promotes growth of commensal bacteria
Peroxidases	Bactericidal properties
Prostaglandin E2	Protects intestinal border and modules immune system
Secretory immunoglobulin A	Immune protection through direct interaction with intestinal pathogens
Soluble intracellular adhesion molecule-1	Alters adhesion of various molecules and pathogens to intestinal epithelium
Transforming growth factor-beta	Immune modulator that limits macrophage expression through NF-kB pathway
Uric acid	Antioxidant properties